Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy.
Julia F SöllnerStefan BentinkChristian HesslingerThomas B LeonardMegan L NeelyNina M PatelThomas SchlangeJamie L ToddRichard ViniskoMargaret L Salisburynull nullPublished in: Lung (2024)
These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.